Protocols

Cancer vax biotech Amal grabs $10M round; Global Blood Therapeutics eyes PRV with new FDA designation

⇨ Geneva-based Amal Therapeutics has picked up about $10 million in Series B money for its work on peptide-based cancer vaccines. Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund invested alongside VI Partners, High-Tech Gründerfonds and Schroder Adveq.

Global Blood Therapeutics $GBT picked up a rare pediatric disease designation for GBT440, putting it in line for a possible priority review voucher.

Enzyvant has also won a rare pediatric disease designation for RVT-802, its therapy for the treatment of primary immune deficiency resulting from congenital athymia associated with complete DiGeorge Syndrome.

BARDA has decided to end funding of Sanofi’s Zika vaccine project. And so Sanofi says it will now stop work on the program — for now at least.

Synergy Pharmaceuticals $SGYP announced today that the company has closed on a $300 million debt financing structured as senior secured loans from CRG.

⇨ Shares of Israel’s Cellect Biotechnology $APOP popped up 40% after the FDA handed over an orphan drug designation for ApoGraft, used for the prevention of acute and chronic graft versus host disease in transplant patients.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 19,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

BioNJ CEO Summit 2017